ARTICLE | Finance
SR One’s newfound freedom allows firm to increase focus on company creation
Former GSK venture arm raises $500M for first fund
November 20, 2020 11:18 PM UTC
SR One’s spinout from GSK gives the newly independent VC the ability to scale up what has been a top-tier investment firm over the past decade, along with the freedom to take larger stakes in portfolio companies and expand its company creation activities.
The firm’s long history as the venture investment arm of U.K. pharma GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) was focused on generating financial returns — a mandate that the firm accomplished in spades...